Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Raquel | - |
dc.creator | Vicente, E. (Esther) | - |
dc.creator | Solano, B. (Beatriz) | - |
dc.creator | Pérez-Silanes, S. (Silvia) | - |
dc.creator | Aldana, I. (Ignacio) | - |
dc.creator | Maddry, J.A. (Joseph A.) | - |
dc.creator | Lenaerts, A.J. (Anne J.) | - |
dc.creator | Franzblau, S.G. (Scott G.) | - |
dc.creator | Cho, S.H. (Sang-Hyun) | - |
dc.creator | Monge, A. (Antonio) | - |
dc.creator | Goldman, R.C. (Robert C.) | - |
dc.date.accessioned | 2013-07-15T08:26:53Z | - |
dc.date.available | 2013-07-15T08:26:53Z | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | Villar R, Vicente E, Solano B, Perez-Silanes S, Aldana I, Maddry JA, et al. In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide. J Antimicrob Chemother 2008 SEP;62(3):547-554 | es_ES |
dc.identifier.issn | 0305-7453 | - |
dc.identifier.uri | https://hdl.handle.net/10171/29498 | - |
dc.description.abstract | Abstract: Objectives: To evaluate a novel series of quinoxaline 1,4-di-N-oxides for in vitro activity against Mycobacterium tuberculosis and for efficacy in a mouse model of tuberculosis (TB). Methods: Ketone and amide derivatives of quinoxaline 1,4-di-N-oxide were evaluated in in vitro and in vivo tests including: (i) activity against M. tuberculosis resistant to currently used antitubercular drugs including multidrug-resistant strains (MDR-TB resistant to isoniazid and rifampicin); (ii) activity against non-replicating persistent (NRP) bacteria; (iii) MBC; (iv) maximum tolerated dose, oral bioavailability and in vivo efficacy in mice; and (v) potential for cross-resistance with another bioreduced drug, PA-824. Results: Ten compounds were tested on single drug-resistant M. tuberculosis. In general, all compounds were active with ratios of MICs against resistant and non-resistant strains of <= 4.00. One compound, 5, was orally active in a murine model of TB, bactericidal, active against NRP bacteria and active on MDR-TB and poly drug-resistant clinical isolates (resistant to 3-5 antitubercular drugs). Conclusions: Quinoxaline 1,4-di-N-oxides represent a new class of orally active antitubercular drugs. They are likely bioreduced to an active metabolite, but the pathway of bacterial activation was different from PA-824, a bioreducible nitroimidazole in clinical trials. Compound 5 was bactericidal and active on NRP organisms indicating that activation occurred in both growing and non-replicating bacteria leading to cell death. The presence of NRP bacteria is believed to be a major factor responsible for the prolonged nature of antitubercular therapy. If the bactericidal activity and activity on non-replicating bacteria in vitro translate to in vivo conditions, quinoxaline 1,4-di-N-oxides may offer a path to shortened therapy. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Oxford University Press | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Antitubercular drugs | es_ES |
dc.subject | Resistance | es_ES |
dc.subject | In vivo efficacy | es_ES |
dc.title | In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | http://dx.doi.org/10.1093/jac/dkn214 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.